March 13th 2023
Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.
February 20th 2023
February 18th 2023
First-Line Pembrolizumab for Urothelial Carcinoma Offers Durable ResponsesJune 22nd 2017
After extended follow-up, the KEYNOTE-052 study has shown that first-line pembrolizumab offers durable responses and no new safety signals in patients with cisplatin-ineligible advanced urothelial cancer.
AUA: Studies Highlight Links Between Bladder Cancer, E-CigarettesMay 15th 2017
New studies at the AUA Annual Meeting highlight the links between smoking and bladder cancer. In one, smoking intensity was linked to survival outcomes, while two others show that electronic cigarettes likely contribute to bladder cancer risk.
Approved Bladder Cancer Drug Fails to Improve Survival in Confirmatory TrialMay 11th 2017
An interim analysis of the phase III IMvigor211 study found that atezolizumab did not meet its primary endpoint of improving overall survival over chemotherapy in patients with locally advanced or metastatic urothelial cancer.
Long-Term Data Confirm CRT Benefit in Muscle-Invasive Bladder CancerFebruary 28th 2017
Long-term data from the phase III BC2001 trial confirmed that adding chemotherapy to radiation therapy improves locoregional control and reduces the rate of salvage cystectomy in patients with muscle-invasive bladder cancer.
rAd-IFNα/Syn3 Promising in BCG-Refractory and Relapsed High-Grade Nonmuscle-Invasive Bladder CancerFebruary 18th 2017
Intravesical rAd-IFNα/Syn3 showed promising response rates, a tolerable treatment schedule, and acceptable toxicity among patients with high-grade, nonmuscle-invasive bladder cancer, refractory or relapsed after bacillus Calmette-Guérin therapy.
Lymph Node Yield Associated With Survival in Upper Urinary Tract CarcinomaFebruary 11th 2017
Though it is used infrequently, lymph node dissection with higher yield of lymph nodes is associated with lower all-cause mortality among patients with urothelial carcinoma of the upper urinary tract who undergo nephroureterectomy.
Chemo After Nephroureterectomy Improves Survival in Upper Tract Urothelial CarcinomaJanuary 12th 2017
In patients with upper tract urothelial carcinoma, adjuvant chemotherapy following radical nephroureterectomy confers a survival advantage compared with observation following radical nephroureterectomy.
ESMO 2016: Pembrolizumab Trial Stops Early, Meets Primary Endpoint in Advanced Bladder CancerNovember 1st 2016
The immune checkpoint antibody pembrolizumab (Keytruda, Merck) improved survival in previously treated advanced urothelial cancer compared to chemotherapy, according to the manufacturer of the immunotherapy.
β-Klotho Gene Linked to Muscle Invasion and Poor PFS in Bladder CancerSeptember 19th 2016
The gene known as β-Klotho (KLβ) appears to play an important role in tumor invasion and progression in patients with bladder cancer, and urine KLβ levels may act as a useful biomarker, according to a new study.
Blocking Osteopontin to Prevent Bladder Cancer MetastasisSeptember 19th 2016
Investigators at the University of Colorado Cancer Center and Yale University are now reporting in the journal Cancer Cell on a new understanding of the cancer suppressing gene RhoDGI2 and how it may be involved in metastatic bladder cancer.